Navigation Links
FRC Urges FDA to Reject New Abortion Drug Falsely Labeled as an Emergency Contraceptive
Date:6/16/2010

WASHINGTON, June 16 /PRNewswire-USNewswire/ -- Tomorrow, the Food and Drug Administration (FDA) will hold a hearing to consider approval of a new drug application for an abortifacient drug, ulipristal acetate, as an emergency contraceptive, or a new "Plan B."

(Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO)

Jeanne Monahan, Family Research Council's Director for the Center for Human Dignity, released the following statement urging the FDA to reject the drug application:

"The drug manufacturer's application is very misleading because the chemical makeup of ulipristal is almost identical to mifepristone, popularly known as RU-486, which is primarily an abortifacient. While the drug can act in a way that inhibits ovulation, it also can act as an abortifacient.

"Women deserve to know the truth about drugs that are marketed to them, and the effects the drugs may have on their health and well-being. The FDA must seriously consider the adverse health effects the drug could have on women, in particular infection and severe bleeding as has been seen with RU-486.

"In the words of the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG), 'Ulipristal acetate is an abortifacient of the same type as mifepristone (RU-486) and... its approval as an emergency contraceptive raises serious health and ethical issues. Furthermore, ulipristal's potential effects on women who used the drug off-label and upon ongoing pregnancies are essentially unexamined and untested.'

"Both ulipristal and mifepristone block the key early pregnancy hormone, progesterone, from functioning properly which effectively starves the embryo. That action potentially can interfere with or end an established pregnancy.

"Women deserve to know what the drug is doing in their body. Preventing human life from beginning is not the same as destroying a life that has already begun. And to many women it is a distinction that makes all the difference.

"We urge the FDA to take seriously its role to protect innocent human life and safeguard the health of American women by rejecting this abortion drug. We also urge a thorough review process to ensure that women's health is not jeopardized just to advance the agenda of the abortion industry."


'/>"/>
SOURCE Family Research Council
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HCD Research Executive Urges Pharmaceutical Industry to Leverage Social Media to Enhance Traditional Marketing Research
2. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
3. DEP Urges Medical Facilities to Take Proper Precautions With X-Ray Equipment to Avoid Health Hazards
4. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
5. Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans
6. Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients
7. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
8. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
9. DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat
10. McCaughey Urges Use of First NYS Hospital Infection Report
11. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Two residents from the ... a video designed to encourage lawmakers to protect Medicaid funding. , The ... Assisted Living (AHCA/NCAL), highlights the story of Chuck and Cathy Schwarz, a couple who ...
(Date:6/27/2017)... York, NY (PRWEB) , ... June 27, 2017 ... ... and marketing experts to contribute to an upcoming case studies guidebook. This guidebook ... her organization. , This book will include articles, case studies and how-to’s that ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance strategies ... experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... . Orthodontics is a dental specialty that focuses on treating alignment and occlusion ... improved aesthetics and function. , North Hollywood dentist , Dr. Garemani, ...
Breaking Medicine News(10 mins):